Masimo Earnings Reports

Masimo delivered a strong third quarter in 2025, with GAAP revenue reaching $371.5 million, an 8.2% increase. The company also achieved a GAAP net income per diluted share of $0.99 and a non-GAAP net income per diluted share of $1.32, representing 38% growth year-over-year. This performance was driven by robust sales growth and successful operating efficiency initiatives, alongside strategic moves like the sale of Sound United and an expanded partnership with Philips.

Masimo delivered strong results in the second quarter of 2025, with GAAP revenue reaching $371 million and non-GAAP diluted EPS growing 46% to $1.33. The company's core healthcare business demonstrated robust growth and earnings, supported by effective tariff mitigation measures.

Masimo delivered solid financial performance in Q1 2025, highlighted by double-digit revenue growth and significant improvement in non-GAAP earnings.

Masimo reported a net loss of $349.6 million for Q4 2024 due to impairment charges related to Sound United. Revenue for the quarter increased by 9% year-over-year, driven by strong healthcare segment performance. Non-GAAP net income per diluted share grew by 44% compared to the prior year period.

Masimo Corporation announced financial results for the third quarter ended September 28, 2024. Consolidated revenue was $504.6 million, with healthcare revenue at $343.3 million and non-healthcare revenue at $161.3 million. GAAP net income per diluted share was $0.18, while non-GAAP net income per diluted share was $0.98.

Masimo reported consolidated revenue of $496.3 million for Q2 2024, with healthcare revenue at $343.9 million and non-healthcare revenue at $152.4 million. GAAP net income per diluted share was $0.29, and non-GAAP net income per diluted share was $0.86. The company increased its full-year 2024 guidance for healthcare revenue, consolidated operating income, and consolidated EPS.

Masimo's consolidated revenue was $492.8 million, with healthcare revenue at $339.6 million and non-healthcare revenue at $153.2 million. The company reported a GAAP net income per diluted share of $0.35 and a non-GAAP net income per diluted share of $0.77.

Masimo reported consolidated revenue of $548.9 million for Q4 2023. GAAP net income per diluted share was $0.63, and non-GAAP net income per diluted share was $1.25. The company's healthcare sector revenue reached $339.9 million, while the non-healthcare sector contributed $209.0 million.

Masimo's consolidated revenue for Q3 2023 was $478.9 million, with healthcare revenue at $307.8 million and non-healthcare revenue at $171.1 million. The company's GAAP net income per diluted share was $0.20, while the non-GAAP net income per diluted share was $0.63. The performance was within the company's guidance range, with the healthcare business undergoing a transition away from COVID-era conditions.

Masimo Corporation reported consolidated revenue of $455.3 million for Q2 2023, with healthcare revenue at $281.1 million and non-healthcare revenue at $174.2 million. GAAP net income was $15.7 million, or $0.29 per diluted share, while non-GAAP net income was $33.7 million, or $0.62 per diluted share. The company gained new hospital customers at a record level but is disappointed with the results due to lower inpatient volumes and delayed large orders.

Masimo reported consolidated revenue of $565.0 million, representing an 85.7% increase compared to the first quarter of 2022. Healthcare revenue grew by 14.0%, while non-healthcare revenue was $218.3 million. GAAP earnings per diluted share were $0.39, and non-GAAP earnings per diluted share were $0.87.

Masimo reported consolidated revenue of $617.0 million, representing an 88.3% increase. Healthcare revenue reached $351.9 million, with a 7.4% reported growth and 10.1% constant currency growth. The company's GAAP net income was $41.1 million, or $0.76 per diluted share, and non-GAAP net income was $71.3 million, or $1.32 per diluted share.

Masimo reported strong Q3 2022 results, with consolidated revenue of $549.3 million, a 78.7% increase compared to Q3 2021. Healthcare revenue grew by 6.4% to $327.2 million, and non-healthcare revenue was $222.1 million. GAAP net income was $37.9 million, or $0.70 per diluted share, while non-GAAP net income was $53.9 million, or $1.00 per diluted share.

Masimo reported consolidated revenue of $565.3 million, representing 85.3% growth compared to Q2 2021. Healthcare revenue was $357.0 million, a 17.0% increase, and non-healthcare revenue was $208.3 million. GAAP net income was $18.1 million, or $0.33 per diluted share, while non-GAAP net income was $74.8 million, or $1.35 per diluted share.

Masimo reported product revenue of $307.4 million, GAAP net income per diluted share of $1.00, and non-GAAP net income per diluted share of $0.94 for the third quarter of 2021.

Masimo reported strong second quarter results with product revenue increasing to $305.1 million and non-GAAP net income per diluted share of $0.94, exceeding expectations due to a strong increase in single-patient-use sensors.

Masimo announced its Q1 2021 financial results, revealing a product revenue increase of 10.9% to $299.0 million compared to Q1 2020. GAAP net income was $53.4 million, or $0.92 per diluted share.

Masimo reported a 19.2% increase in total revenue for the fourth quarter of 2020, reaching $295.1 million compared to $247.5 million in the fourth quarter of 2019. GAAP net income per diluted share was $1.21, and non-GAAP net income per diluted share was $0.98.

Masimo announced its Q3 2020 financial results, with total revenue increasing by 21.4% to $278.1 million compared to Q3 2019. Product revenue also increased by 21.5% to $278.1 million. GAAP net income was $49.4 million, or $0.85 per diluted share, while non-GAAP net income was $46.8 million, or $0.80 per diluted share.

Masimo reported a 31.0% increase in total revenue to $301.0 million for Q2 2020, with product revenue also up by 31.1%. GAAP net income per diluted share was $0.96, and non-GAAP net income per diluted share was $0.85. Shipments of noninvasive technology boards and instruments reached a record 165,600.

Masimo reported a 16.4% increase in total revenue to $269.6 million for Q1 2020, driven by a 16.9% increase in product revenue. GAAP net income per diluted share was $1.12, and non-GAAP net income per diluted share was $0.97. The company shipped 72,100 noninvasive technology boards and monitors, a 13.2% increase year-over-year.

Masimo reported a total revenue of $247.5 million for Q4 2019, with product revenue increasing by 11.8% to $247.4 million. The company's GAAP net income per diluted share was $0.92, and non-GAAP net income per diluted share was $0.91.